Yasir Al-Wakeel

Dr. Al-Wakeel currently serves as CFO and Head of Corporate Development for Kronos Bio, where he was instrumental in the company’s $288 million IPO. He previously served as CFO and Strategy Officer at Neon Therapeutics (now BioNTech) and was CFO and Head of Corporate Development at Merrimack Pharmaceuticals (now Ipsen). Prior to those roles, Dr. Al-Wakeel served in senior roles in equity research and corporate finance at Credit Suisse focused on the biotechnology sector. Dr. Al-Wakeel began his career as a practicing physician, holding both clinical and academic medical posts in the United Kingdom. He holds a BM BCh from Oxford University and an MA in theology from Cambridge University.